查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1517673

自体细胞治疗市场 - 全球产业规模、份额、趋势、机会和预测，按来源、应用、最终用户、地区和竞争细分，2019-2029F

Autologous Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球自体细胞治疗市场估值为55.2 亿美元，预计到2029 年将在预测期内稳定成长，复合年增长率为5.25%。提供创新的解决方案。在多种细胞治疗方法中，自体细胞治疗脱颖而出，成为个人化医疗的一种有前途的途径。近年来，在再生医学的进步、慢性病盛行率的增加以及对个人化治疗策略的日益重视的推动下，全球自体细胞治疗市场出现了显着增长。

市场概况
预测期 2025-2029
2023 年市场规模 55.2亿美元
2029 年市场规模 75.2亿美元
2024-2029 年复合年增长率 5.25%
成长最快的细分市场 癌症
最大的市场 北美洲

自体细胞疗法涉及利用患者自身的细胞（通常来自血液、骨髓或脂肪组织），然后处理和重新施用这些细胞来治疗特定的病症。这种方法消除了与同种异体疗法相关的排斥或併发症的风险，因为细胞来自接受治疗的同一个体。自体细胞疗法的个人化性质提高了其安全性和有效性。

主要市场驱动因素

慢性病盛行率上升正在推动全球自体细胞治疗市场

不断提高的意识和接受度正在推动全球自体细胞治疗市场

主要市场挑战

初始成本高且报销有限

主要市场趋势

技术进步

细分市场洞察

来源洞察

应用见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依来源分类（骨髓、表皮、间质干细胞、造血干细胞、软骨细胞、其他）
    • 依应用分类（癌症、神经退化性疾病、心血管疾病、自体免疫疾病、骨科、伤口癒合、其他）
    • 按最终使用者（医院和诊所、门诊中心、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 按来源
    • 按申请
    • 按最终用户
    • 按地区

第 6 章：北美自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按来源
    • 按申请
    • 按最终用户
    • 按国家/地区

第 7 章：欧洲自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按来源
    • 按申请
    • 按最终用户
    • 按国家/地区

第 8 章：亚太地区自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按来源
    • 按申请
    • 按最终用户
    • 按国家/地区

第 9 章：南美洲自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按来源
    • 按申请
    • 按最终用户
    • 按国家/地区

第 10 章：中东和非洲自体细胞治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按来源
    • 按申请
    • 按最终用户
    • 按国家/地区

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第13章：竞争格局

  • Biomatrica, Inc.
  • Holostem Terapie Avanzate SRL
  • Pharmicell Co. Inc
  • Caladrius Biosciences Inc
  • US Stem Cell Inc
  • Bristol Myers Squibb Company
  • Corning Incorporated
  • Vericel Corporation
  • Catalent, Inc
  • Sartorius AG

第 14 章：策略建议

第15章调查会社について・免责事项

简介目录
Product Code: 23869

Global Autologous Cell Therapy Market was valued at USD 5.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Cell therapy has emerged as a revolutionary field in medical science, offering innovative solutions to various health challenges. Among the diverse approaches to cell therapy, autologous cell therapy stands out as a promising avenue for personalized medicine. The global autologous cell therapy market has witnessed significant growth in recent years, driven by advancements in regenerative medicine, increasing prevalence of chronic diseases, and a growing emphasis on personalized treatment strategies.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.52 Billion
Market Size 2029USD 7.52 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentCancer
Largest MarketNorth America

Autologous cell therapy involves harnessing the patient's own cells, typically from blood, bone marrow, or adipose tissue, and then processing and re-administering these cells to treat a specific condition. This approach eliminates the risk of rejection or complications associated with allogeneic therapies, as the cells are derived from the same individual receiving the treatment. The personalized nature of autologous cell therapy enhances its safety profile and effectiveness.

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Autologous Cell Therapy Market

The global healthcare landscape is witnessing a significant paradigm shift with the increasing prevalence of chronic diseases. Conditions such as diabetes, cardiovascular diseases, and various forms of cancer are on the rise, posing a substantial challenge to healthcare systems worldwide. In response to this alarming trend, there has been a growing focus on innovative and personalized treatment approaches, with autologous cell therapy emerging as a promising solution. Autologous cell therapy involves the extraction, manipulation, and reintroduction of a patient's own cells to treat or prevent diseases. This personalized approach harnesses the regenerative potential of cells to repair damaged tissues and restore normal physiological function. The therapy relies on various cell types, including mesenchymal stem cells, T cells, and hematopoietic stem cells, among others.

The prevalence of chronic diseases is escalating at an alarming rate, posing a substantial burden on healthcare systems globally. Factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population contribute to the surge in conditions like diabetes, cardiovascular diseases, and cancer. Conventional treatment modalities often fall short in providing long-lasting and effective solutions, necessitating a shift towards more advanced and personalized therapeutic approaches. Autologous cell therapy has garnered attention for its ability to address the limitations of traditional treatments. By leveraging the patient's own cells, the therapy minimizes the risk of immune rejection and adverse reactions, offering a safer and more efficient alternative. This personalized approach also holds the potential to target the root cause of diseases, leading to improved clinical outcomes and enhanced quality of life for patients.

The global autologous cell therapy market is witnessing robust growth, driven by the increasing prevalence of chronic diseases and the demand for personalized treatment options. The market encompasses a diverse range of applications, including orthopedic, cardiovascular, neurologic, and oncologic disorders. Companies specializing in cell therapy research and development are actively expanding their portfolios to capitalize on the growing market opportunities. The regulatory landscape is evolving to support the development and commercialization of autologous cell therapy. Regulatory bodies are working closely with industry stakeholders to establish clear guidelines and standards for the safe and effective implementation of these therapies. Moreover, continuous advancements in biotechnology and cell culture techniques are enhancing the scalability and affordability of autologous cell therapy, making it more accessible to a broader patient population.

Growing Awareness and Acceptance is Driving the Global Autologous Cell Therapy Market

Autologous cell therapy, a cutting-edge medical approach harnessing the power of an individual's own cells to treat various diseases and conditions, is experiencing a surge in global demand. This revolutionary field has witnessed significant growth, fueled by growing awareness and acceptance among both healthcare professionals and the general public. As research continues to unveil the potential of autologous cell therapy, the market is poised for unprecedented expansion. Medical professionals are increasingly recognizing the potential of autologous cell therapy in providing targeted and personalized treatments. Clinical trials and research publications showcasing positive outcomes have contributed to the growing acceptance of these therapies within the medical community. Patients are becoming more proactive in managing their healthcare and are seeking personalized treatment options that offer fewer side effects and better outcomes. Autologous cell therapy aligns with this shift towards patient-centric healthcare, providing tailored solutions that The global autologous cell therapy market is poised for significant expansion in the coming years. Emerging applications, such as the use of cell therapies in orthopedics, dermatology, and autoimmune diseases, are expected to contribute to market growth. Additionally, advancements in manufacturing processes and the development of scalable production techniques are likely to enhance the accessibility of autologous cell therapies.

While the outlook for autologous cell therapy is promising, challenges such as high treatment costs, complex manufacturing processes, and the need for standardized protocols must be addressed. Collaborative efforts between researchers, industry stakeholders, and regulatory bodies will be crucial in overcoming these hurdles and ensuring the widespread adoption of autologous cell therapies. The global autologous cell therapy market is experiencing robust growth, driven by increasing awareness, acceptance, and a growing understanding of the therapeutic potential of personalized cell-based treatments. As research continues to unravel the full spectrum of possibilities within this field, the future holds promise for innovative and effective solutions to a wide array of medical challenges. address individual needs.

Key Market Challenges

High Initial Costs and Limited Reimbursement

The initial phase of developing autologous cell therapies involves extensive research to understand the specific cell types, their functions, and how they can be manipulated to achieve therapeutic goals. This process demands significant financial investments in laboratories, equipment, and skilled researchers. The regulatory approval process for any medical intervention, including autologous cell therapies, requires rigorous and lengthy clinical trials. These trials involve large-scale testing to ensure safety and efficacy. Conducting trials on a diverse group of patients, monitoring outcomes, and meeting regulatory standards all contribute to the soaring costs.

Establishing the necessary infrastructure for manufacturing autologous cell therapies demands advanced technologies and specialized facilities. Maintaining cleanroom environments, acquiring state-of-the-art equipment, and implementing stringent quality control measures add to the overall expenses. Unlike traditional pharmaceuticals, autologous cell therapies involve the extraction, processing, and administration of a patient's own cells. Managing the logistics of a personalized supply chain adds complexity and cost to the production and delivery processes. Meeting the regulatory requirements for cell therapies is a resource-intensive task. Companies must invest in navigating complex regulatory landscapes to ensure compliance with safety and quality standards set by health authorities worldwide.

Key Market Trends

Technological Advancements

In recent years, the field of regenerative medicine has witnessed unprecedented growth, with autologous cell therapy emerging as a revolutionary approach to treating various diseases and conditions. Technological advancements play a pivotal role in propelling the Global Autologous Cell Therapy Market, fostering innovation, and unlocking new possibilities for personalized medicine. One of the key drivers of the Autologous Cell Therapy Market is the shift towards personalized medicine. Advancements in technology have allowed for the isolation and manipulation of a patient's own cells, offering a tailor-made therapeutic approach. This personalized strategy minimizes the risk of immune rejection and enhances treatment efficacy, leading to a surge in the adoption of autologous cell therapies across various medical domains.

In the realm of autologous cell therapy, the cultivation and expansion of cells outside the body are critical processes. Technological innovations have significantly improved cell culture techniques, enabling researchers and clinicians to obtain a sufficient quantity of high-quality cells for therapeutic applications. Advanced bioreactors, automated systems, and optimized culture media have streamlined the production of autologous cell therapies, making them more scalable and cost-effective. The advent of genetic engineering and gene editing tools, such as CRISPR-Cas9, has revolutionized the field of autologous cell therapy. These tools allow scientists to modify the genetic makeup of cells, enhancing their therapeutic potential. With the ability to precisely edit genes, researchers can optimize cells for specific functions, improve their survival rates in the body, and even introduce therapeutic genes to combat diseases at the genetic level.

Accurate monitoring and assessment of the administered autologous cell therapies are crucial for ensuring their safety and efficacy. Advanced imaging technologies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), provide real-time insights into the behavior and integration of transplanted cells within the patient's body. This level of monitoring not only enhances the understanding of the therapy's mechanisms but also helps in refining treatment protocols for better patient outcomes. Automation and robotics have significantly improved the efficiency and reproducibility of cell processing in autologous cell therapy. Automated systems facilitate the isolation, purification, and manipulation of cells with precision, reducing the risk of contamination and human errors. This has not only accelerated the production timelines but has also standardized the manufacturing processes, making autologous cell therapies more reliable and accessible. The growing acceptance and success of autologous cell therapy has prompted regulatory bodies to establish supportive frameworks. Continuous engagement with regulatory authorities, coupled with advancements in technology, has led to clearer guidelines and streamlined approval processes. This has created a conducive environment for research and development, fostering innovation and investment in the Autologous Cell Therapy Market.

Segmental Insights

Source Insights

Based on the category of source, Bone Marrow emerged as the dominant segment in the global market for Autologous Cell Therapy in 2023. Bone marrow has long been recognized as a rich source of multipotent stem cells, including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). HSCs have the ability to differentiate into various blood cell types, while MSCs can differentiate into bone, cartilage, and fat cells. This versatility makes bone marrow an ideal source for autologous cell therapy, allowing for the treatment of a wide range of conditions, from blood disorders to orthopedic issues.

The versatility of bone marrow-derived cells makes them suitable for addressing diverse medical conditions. Hematopoietic stem cells are commonly used in the treatment of hematological disorders such as leukemia and lymphoma. Mesenchymal stem cells, on the other hand, have shown promise in treating orthopedic conditions, autoimmune diseases, and even neurological disorders. Several clinical trials and success stories highlight the effectiveness of bone marrow-derived cells in autologous cell therapy. In orthopedics, for example, MSCs extracted from bone marrow have been used to promote the regeneration of damaged tissues in conditions like osteoarthritis and tendon injuries. In the realm of blood disorders, hematopoietic stem cells from bone marrow have played a pivotal role in the treatment of leukemia and other hematologic malignancies.

Applications Insights

The cancer segment is projected to experience rapid growth during the forecast period. The rising global incidence of cancer has contributed significantly to the dominance of cancer treatments in the autologous cell therapy market. With an increasing number of cancer cases worldwide, there is a growing demand for innovative and effective treatment options. Autologous cell therapies exhibit remarkable versatility in targeting various forms of cancer. These therapies, such as CAR-T cell therapy, have shown promising results in treating hematological malignancies like leukemia and lymphoma. Ongoing research is expanding the application of autologous cell therapy to solid tumors, further establishing its dominance in cancer treatment.

One of the key advantages of autologous cell therapy is its ability to be customized for each patient. Cancer is a highly heterogeneous disease, and personalized cell therapies address this heterogeneity by tailoring treatments to individual genetic and molecular profiles. This level of customization enhances treatment efficacy and contributes to cancer's prominence in the autologous cell therapy market. The remarkable success stories of autologous cell therapy in clinical trials and real-world applications have generated significant attention and investor interest. Successful outcomes, especially in cases where conventional treatments have failed, have positioned cancer treatments as frontrunners in the global autologous cell therapy market. The pharmaceutical and biotechnology industries have heavily invested in research and development of autologous cell therapies for cancer treatment. This focus on cancer has led to accelerated advancements, clinical trials, and regulatory approvals, further establishing its dominance in the autologous cell therapy landscape.

Regional Insights

North America emerged as the dominant region in the global Autologous Cell Therapy market in 2023, holding the largest market share in terms of value. North America boasts a robust research and development infrastructure, with numerous cutting-edge laboratories, academic institutions, and biotechnology companies dedicated to advancing cell therapy technologies. The region's commitment to scientific innovation has resulted in a steady stream of breakthroughs and novel therapies, positioning it at the forefront of the autologous cell therapy market. The United States, in particular, has been a hub for pioneering clinical trials in the autologous cell therapy space. The country's regulatory bodies, such as the Food and Drug Administration (FDA), have shown a proactive approach in facilitating the development and approval of autologous cell therapies. This regulatory support has encouraged both domestic and international companies to conduct extensive clinical trials in the region, further solidifying North America's dominance.

Key Market Players

Biomatrica, Inc.

Holostem Terapie Avanzate S.R.L

Pharmicell Co. Inc

Caladrius Biosciences Inc

U.S. Stem Cell Inc

Bristol Myers Squibb Company

Corning Incorporated

Vericel Corporation

Catalent, Inc

Sartorius AG

Report Scope:

In this report, the Global Autologous Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autologous Cell Therapy Market, By Source:

    Bone Marrow Epidermis Mesenchymal Stem Cells Haematopoietic Stem Cells Chondrocytes Others

Autologous Cell Therapy Market, By Application:

    Cancer Neurodegenerative Disorders Cardiovascular Disorders Autoimmune Disorders Orthopedics Wound Healing Others

Autologous Cell Therapy Market, By End User:

    Hospitals & Clinics Ambulatory Centers Others

Autologous Cell Therapy Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Autologous Cell Therapy Market.

Available Customizations:

Global Autologous Cell Therapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autologous Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes, Others)
    • 5.2.2. By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Source
    • 5.3.2. By Application
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Autologous Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. United States Autologous Cell Therapy Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Source
        • 6.2.4.1.2.2. By Application
        • 6.2.4.1.2.3. By End User
      • 6.2.4.2. Canada Autologous Cell Therapy Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Source
        • 6.2.4.2.2.2. By Application
        • 6.2.4.2.2.3. By End User
      • 6.2.4.3. Mexico Autologous Cell Therapy Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Source
        • 6.2.4.3.2.2. By Application
        • 6.2.4.3.2.3. By End User

7. Europe Autologous Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. France Autologous Cell Therapy Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Source
        • 7.2.4.1.2.2. By Application
        • 7.2.4.1.2.3. By End User
      • 7.2.4.2. Germany Autologous Cell Therapy Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Source
        • 7.2.4.2.2.2. By Application
        • 7.2.4.2.2.3. By End User
      • 7.2.4.3. United Kingdom Autologous Cell Therapy Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Source
        • 7.2.4.3.2.2. By Application
        • 7.2.4.3.2.3. By End User
      • 7.2.4.4. Italy Autologous Cell Therapy Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Source
        • 7.2.4.4.2.2. By Application
        • 7.2.4.4.2.3. By End User
      • 7.2.4.5. Spain Autologous Cell Therapy Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Source
        • 7.2.4.5.2.2. By Application
        • 7.2.4.5.2.3. By End User

8. Asia Pacific Autologous Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. China Autologous Cell Therapy Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Source
        • 8.2.4.1.2.2. By Application
        • 8.2.4.1.2.3. By End User
      • 8.2.4.2. India Autologous Cell Therapy Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Source
        • 8.2.4.2.2.2. By Application
        • 8.2.4.2.2.3. By End User
      • 8.2.4.3. South Korea Autologous Cell Therapy Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Source
        • 8.2.4.3.2.2. By Application
        • 8.2.4.3.2.3. By End User
      • 8.2.4.4. Japan Autologous Cell Therapy Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Source
        • 8.2.4.4.2.2. By Application
        • 8.2.4.4.2.3. By End User
      • 8.2.4.5. Australia Autologous Cell Therapy Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Source
        • 8.2.4.5.2.2. By Application
        • 8.2.4.5.2.3. By End User

9. South America Autologous Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Autologous Cell Therapy Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Source
        • 9.2.4.1.2.2. By Application
        • 9.2.4.1.2.3. By End User
      • 9.2.4.2. Argentina Autologous Cell Therapy Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Source
        • 9.2.4.2.2.2. By Application
        • 9.2.4.2.2.3. By End User
      • 9.2.4.3. Colombia Autologous Cell Therapy Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Source
        • 9.2.4.3.2.2. By Application
        • 9.2.4.3.2.3. By End User

10. Middle East & Africa Autologous Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Autologous Cell Therapy Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Source
        • 10.2.4.1.2.2. By Application
        • 10.2.4.1.2.3. By End User
      • 10.2.4.2. Saudi Arabia Autologous Cell Therapy Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Source
        • 10.2.4.2.2.2. By Application
        • 10.2.4.2.2.3. By End User
      • 10.2.4.3. UAE Autologous Cell Therapy Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Source
        • 10.2.4.3.2.2. By Application
        • 10.2.4.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Biomatrica, Inc.
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. Holostem Terapie Avanzate S.R.L
  • 13.3. Pharmicell Co. Inc
  • 13.4. Caladrius Biosciences Inc
  • 13.5. U.S. Stem Cell Inc
  • 13.6. Bristol Myers Squibb Company
  • 13.7. Corning Incorporated
  • 13.8. Vericel Corporation
  • 13.9. Catalent, Inc
  • 13.10. Sartorius AG

14. Strategic Recommendations

15. About us & Disclaimer